JP5269767B2 - インスリン誘導体 - Google Patents

インスリン誘導体 Download PDF

Info

Publication number
JP5269767B2
JP5269767B2 JP2009508373A JP2009508373A JP5269767B2 JP 5269767 B2 JP5269767 B2 JP 5269767B2 JP 2009508373 A JP2009508373 A JP 2009508373A JP 2009508373 A JP2009508373 A JP 2009508373A JP 5269767 B2 JP5269767 B2 JP 5269767B2
Authority
JP
Japan
Prior art keywords
insulin
amide
insulin derivative
chain
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009508373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536179A (ja
JP2009536179A5 (enExample
Inventor
フランチセク フバレク，
トマス ヘーグ−イェンセン，
イブ ヨナセン，
パトリック ウィリアム ガリベイ，
パレ ヤコブセン，
スヴェンド ハヴェルンド，
ヨノス ティボー コドラ，
Original Assignee
ノボ・ノルデイスク・エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボ・ノルデイスク・エー／エス filed Critical ノボ・ノルデイスク・エー／エス
Publication of JP2009536179A publication Critical patent/JP2009536179A/ja
Publication of JP2009536179A5 publication Critical patent/JP2009536179A5/ja
Application granted granted Critical
Publication of JP5269767B2 publication Critical patent/JP5269767B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2009508373A 2006-05-09 2007-05-08 インスリン誘導体 Expired - Fee Related JP5269767B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06113709 2006-05-09
EP06113709.7 2006-05-09
EP06118260 2006-08-01
EP06118260.6 2006-08-01
PCT/EP2007/054444 WO2007128817A2 (en) 2006-05-09 2007-05-08 Insulin derivative

Publications (3)

Publication Number Publication Date
JP2009536179A JP2009536179A (ja) 2009-10-08
JP2009536179A5 JP2009536179A5 (enExample) 2010-06-24
JP5269767B2 true JP5269767B2 (ja) 2013-08-21

Family

ID=38668119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009508373A Expired - Fee Related JP5269767B2 (ja) 2006-05-09 2007-05-08 インスリン誘導体

Country Status (13)

Country Link
US (1) US8933021B2 (enExample)
EP (2) EP2386572B1 (enExample)
JP (1) JP5269767B2 (enExample)
KR (1) KR101441444B1 (enExample)
AU (1) AU2007247109B2 (enExample)
BR (1) BRPI0712041A2 (enExample)
CA (1) CA2649235A1 (enExample)
ES (2) ES2395738T3 (enExample)
IL (1) IL194312A0 (enExample)
MX (1) MX2008014061A (enExample)
NO (1) NO20085056L (enExample)
RU (1) RU2451029C2 (enExample)
WO (1) WO2007128817A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2107069B1 (en) * 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
EP1846447B1 (en) * 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
EP2505593A1 (en) * 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
US20120214963A1 (en) * 2011-02-23 2012-08-23 Elona Biotechnologies Aspart proinsulin compositions and methods of producing aspart insulin analogs therefrom
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101932601B (zh) * 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
CA2705821A1 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
PT2910570T (pt) 2008-03-18 2017-01-24 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
AU2009309623B9 (en) * 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP2013514322A (ja) 2009-12-16 2013-04-25 ノヴォ ノルディスク アー／エス 修飾されたｎ末端を有するｇｌｐ−１受容体アゴニスト化合物
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
EP2632478B1 (en) * 2010-10-27 2019-07-24 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
PL3326620T3 (pl) 2010-12-16 2020-08-24 Novo Nordisk A/S Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego
MX342922B (es) * 2011-02-01 2016-10-19 Novo Nordisk As Purificacion de insulina.
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
ES2712945T3 (es) * 2011-04-12 2019-05-16 Novo Nordisk As Derivados de GLP-1 doblemente acilados
BR112013026195A2 (pt) 2011-04-12 2016-11-29 Novo Nordisk As derivados de glp-1 duplamente acilados
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
US9884094B2 (en) 2012-05-01 2018-02-06 Novo Nordisk A/S Method of treating diabetes mellitus
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
PT3055325T (pt) 2013-10-07 2018-04-06 Novo Nordisk As Novo derivado de um análogo de insulina
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
PT3554534T (pt) 2016-12-16 2021-11-05 Novo Nordisk As Composições farmacêuticas contendo insulina
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
BR112021011050A2 (pt) 2018-12-11 2021-08-31 Sanofi Ligante peptídico
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
US20240239862A1 (en) * 2019-12-30 2024-07-18 Gan & Lee Pharmaceuticals Co., Ltd. Insulin Derivative

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
WO1990007522A1 (en) 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
JP3018463B2 (ja) * 1989-10-19 2000-03-13 日本油脂株式会社 グルコース応答性薬物放出複合体
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
DE122004000035I2 (de) 1993-09-17 2009-08-06 Novo Nordisk As Acyliertes insulin
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AU720966B2 (en) * 1995-03-17 2000-06-22 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
JP3300368B2 (ja) * 1996-07-11 2002-07-08 ノボ ノルディスク アクティーゼルスカブ 選択的アシル化方法
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
WO2003075950A1 (en) 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2005005477A2 (en) * 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
AU2004261319B2 (en) * 2003-07-25 2010-12-23 Conjuchem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
CA2546243A1 (en) 2003-11-14 2005-05-26 University Of Tennessee Research Corporation The mycolactone locus : an assembly line for producing novel polyketides, with therapeutic and prophylatic uses
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
US20070221884A1 (en) 2004-07-16 2007-09-27 Holger Hoppe Liminescent Silicon Oxide Flakes
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
EP1846447B1 (en) 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
DE102005062618B4 (de) 2005-12-23 2008-05-08 Carl Zeiss Smt Ag Optische Abbildungseinrichtung und Abbildungsverfahren mit Bestimmung von Abbildungsfehlern
EP2505593A1 (en) * 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
EP1996223A1 (en) * 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
EP2024390B1 (en) * 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
CN101932601B (zh) 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
WO2009060072A1 (de) 2007-11-09 2009-05-14 Mann+Hummel Gmbh Filterelement für flüssigkeitsfilter und flüssigkeitsfilter
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US20130143803A1 (en) 2010-05-10 2013-06-06 Novo Nordisk A/S Process for the Preparation of Insulin-Zinc Complexes
WO2011141408A2 (de) 2010-05-10 2011-11-17 Basf Se Thermoplastisches polyurethan enthaltend glycerin, das mit mindestens einer aliphatischen carbonsäure verestert ist als weichmacher

Also Published As

Publication number Publication date
MX2008014061A (es) 2008-11-14
BRPI0712041A2 (pt) 2011-12-27
WO2007128817A2 (en) 2007-11-15
JP2009536179A (ja) 2009-10-08
IL194312A0 (en) 2011-08-01
EP2386572B1 (en) 2015-07-08
WO2007128817A3 (en) 2008-03-06
EP2386572A1 (en) 2011-11-16
NO20085056L (no) 2008-12-03
RU2008143668A (ru) 2010-06-20
CA2649235A1 (en) 2007-11-15
KR20090018906A (ko) 2009-02-24
US8933021B2 (en) 2015-01-13
KR101441444B1 (ko) 2014-09-18
US20090239785A1 (en) 2009-09-24
EP2015770B1 (en) 2012-09-26
AU2007247109B2 (en) 2012-03-15
ES2395738T3 (es) 2013-02-14
RU2451029C2 (ru) 2012-05-20
AU2007247109A1 (en) 2007-11-15
ES2548393T3 (es) 2015-10-16
EP2015770A2 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
JP5269767B2 (ja) インスリン誘導体
JP5269766B2 (ja) インスリン誘導体
JP5202338B2 (ja) 新規インシュリン誘導体
JP5715418B2 (ja) インスリン誘導体
JP5818681B2 (ja) インスリンアルブミンコンジュゲート
JP5410020B2 (ja) インスリン誘導体
JP5495785B2 (ja) アミノ酸伸長したインスリン
JP5730569B2 (ja) アシル及びアルキレングリコール部分を有するインスリンアナログ
EP2505593A1 (en) Compositions comprising an acylated insulin and zinc and method of making the said compositions
CN101437849B (zh) 胰岛素衍生物
EP2058330A1 (en) Insulin derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130508

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees